Fibronectin serves as a platform to guide and facilitate deposition of collagen and fibrillin microfibrils. During development of fibrotic diseases, altered fibronectin deposition in the extracellular matrix (ECM) is generally an early event. Following this, dysregulated organization of fibrillins and fibrillar collagens occurs. Because fibronectin is an essential orchestrator of healthy ECM, perturbation of its ECM-organizational capacity may be involved in development of fibrosis. To investigate this, we employed recessive dystrophic epidermolysis bullosa (RDEB) as a disease model with progressive, severe dermal fibrosis. Fibroblasts from RDEB donors in 2D and 3D cultures displayed dysregulated fibronectin deposition. Our analyses revealed that increase of pro-fibrotic DPP4+ fibroblasts coincides with altered fibronectin deposition. DPP4 inhibitors normalized deposition of fibronectin and subsequently of fibrillin microfibrils and collagen I. Intriguingly, proteomics, inhibitor and mutagenesis studies disclosed that DPP4 modulates ECM deposition through proteolysis of the fibronectin N-terminus. Our study provides mechanistic insights to the observed pro-fibrotic activities of DPP4 and extends the understanding of fibronectin-guided ECM assembly in health and disease.
Fibril formation by amyloidogenic proteins and peptides is considered the cause of a number of incurable diseases. One of the most known amyloid diseases is Alzheimer’s disease (AD). Traditionally, amyloidogenic beta peptides Aβ40 and Aβ42 (Aβs) are considered as main causes of AD and the foremost targets in AD fight. The main efforts in pharmacology are aimed at reducing Aβs concentration to prevent their accumulation, aggregation, formation of senile plaques, neuronal death, and neurodegeneration. However, a number of publications have demonstrated certain beneficial physiological effects of Aβs. Simultaneously, it is indicated that the effects of Aβs turn into pathological due to the development of certain diseases in the body. The accumulation of C- and N-terminal truncated Aβs under diverse conditions is supposed to play a role in AD development. The significance of transformation of glutamate residue at positions 3 or 11 of Aβs catalyzed by glutaminyl cyclase making them more degradation resistant, hydrophobic, and prone to aggregation, as well as the participation of dipeptidyl peptidase IV in these transformations are discussed. The experimental data presented confirm the maintenance of physiological, nonaggregated state of Aβs by plant preparations. In conclusion, this review suggests that in the fight against AD, instead of removing Aβs, preference should be given to the treatment of common diseases. Glutaminyl cyclase and dipeptidyl peptidase IV can be considered as targets in AD treatment. Flavonoids and plant preparations that possess antiamyloidogenic propensity are proposed as beneficial neuroprotective, anticancer, and antidiabetic food additives.
The water and DMSO solutions of two new synthesized compounds, β-dimethylaminoethylamidine N-benzoyl-DL-valineiodomethylate (TVA) and 1-(β-diethylaminoethyl)-2-phenyl-4-benzylidene-5-imidazolone (TVS), were characterized by optical absorbance and fluorescence properties. Earlier, the antiacetylcholinesterase and antibutyrylcholinesterase activities of these compounds have been shown. To prove the eligibility of their use against Alzheimer’s disease, the present study demonstrates the ability of the compounds to reduce the aggregation degree of commercial Aβ(1-42) amyloid peptide in vitro. From the concentration dependences, their IC50 values were estimated in the deceleration of Aβ(1-42) aggregation (1.56 ± 0.3 mM for TVA and 1.8 ± 0.28 mM for TVS). The effective destabilization of the preformed aggregates of the peptide was registered with the IC50 values of 0.54 ± 0.06 and 0.67 ± 0.2 mM, for TVA and TVS, respectively. Cell culture experiments have shown the effectiveness of the synthesized compounds in protection the rat hippocampal cells against cytotoxic action of Aβ(1-42) aggregates: during 7 days incubation, the number of neurospheres per microscopic field in the presence of the peptide aggregates fallen down to 34% of the intact cells, but 2 μg/mL TVA kept the cells on the level of the intact, and 5 μg/mL TVS—on the level of 77% of the intact. Subsequent developments based on these compounds will allow the researchers to create the preparations valid for pre-clinical studies with goal to introduce into medical practice as new remedies in prevention/treatment of Alzheimer’s disease.